Abstract: P.mirabilis is considered one of the nosocomial infection causative agent, and its importance is related with the wide separation in different ecosystem, in addition to its relationship with renal and bile calculi ,and because of an increase of bacterial resistance, this study goal to find substitutional substance used to treat bacterial infection through using natural biomaterial, thus using LPS (Lipid A moiety) as adjuvant immunotherapy by different routes of administration(Oral, intraperitoneal, and subcutaneous) and find the best one. The results showed, recovered lipid A was obtained from both collected LPS of pathogenic P.mirabilis isolate and standard bacteria approximately represented 20% of LPS amount, with LD50 0.6 ϻg/ml for the pathogenic one. The estimation of some immune parameters such as IL-1β showed i.p administration was led to a significant elevation of this interleukin in compared with other routes and control groups. Meanwhile, IL-2, IL-10, and IFN-γ percentages showed a significant elevation in all treated groups in compared with control. While TNF-α percentage revealed variation in levels according to the route of administration, simultaneously both intraperitoneal and subcutaneous routes showed a significant elevation. Whereas the IgG level exhibited, no significant alteration observed with any treated groups in compared with control one.
Introduction
Lipid A is the hydrophobic anchor of lipopolysaccharide, which forms the outer monolayer of the outer membranes of most gram-negative bacteria. It is embedded in a matrix of phospholipid and protein (1, 2) .It is the most conservative part of LPS, which is responsible for its toxicity and it has a specific effect on monocytes and macrophages. In macrophage, lipid A triggers the synthesis of diverse inflammatory mediators, such as TNF-α and IL1-β, as well as enhance the production of co-stimulatory molecules, which is needed for the adaptive immune response, While in mononuclear and endothelial cells, lipid A enhances tissue factor production (3) . On the other hand, adjuvants are compound which increases the immunogenicity of the antigens and act to up-regulate immune responses to improve vaccine efficacy and efficiency (4) . They differ in their mode of action, some of them are capable to transfer long-term presentation of the antigen, which is known as depot effect, whereas others assist to target immune cells as in delivering the antigen to APCs or by showing a capacity to enhance the production of different cytokine patterns by activating different pattern-recognition-receptors (PRRs), and shifting the immune response towards Th-1 or Th-2, another possibility, the adjuvant may enhance the levels of co-stimulatory molecules on APCs (5) . The experiment of chemically modified LPS concluded that only the lipid A part is needed for adjuvanticity. The most desirable characteristics of modern adjuvant vaccines are the safety, reactogenicity, and the ability to increase a specific efficacy of the vaccine (6, 7) . The removal of endotoxins from materials designed for use on humans, as well as the animals considered as an important field of study in applied biotechnological science (3) .Thus this study was aimed to assess using of lipid A extracted from Proteus mirabilis LPS as adjuvant immunotherapy with the suitable route of administration .
Materials and Methods
Depending on previous study (8) 
Immunization schedule
Mice in each group were injected daily for seven days and monitored for 14 days from the first dose. The blood sample was pooled from the heart using a 3ml syringe and transferred into gel tube, centrifuged and the serum was stored at -20•C for further immunological parameter studies.
Preparation of killed Staphylococcus aureus vaccine (11)
In order to prepare the Staphylococcus aureus killed vaccine. S.aureus was activated by inoculated into tryptic soy broth/himedia (India), incubated for 24 hours at 37•C. Killed vaccine was prepared by heating the culture at 100•C for 30 min. Finally, the vaccine sterility was tested by streaking loop full of heat treated bacterial suspension on nutrient agar/ himedia (India), and incubated overnight at 37•C.
The bacterial suspension was centrifuged and the bacterial pellet was washed 3 times with distilled water, the sediment was collected and used as a killed bacterial antigen for the vaccine, and the concentration of bacterial growth was counted by comparing with the McFarland standard solution (1 X 10 8 ).
Challenge test
The numbers of 15 mice were divided into 3 groups, each one included 5 mice. They were immunized (orally, subcutaneously and intraperitoneal ) with 30ϻl of prepared vaccine mixture (25ϻl killed vaccine +5ϻl lipid A (0.6ϻg/ml)), then a booster dose was given after a week from the first one and monitored another week. All groups of animals, (control and treated) were deeply scratched in the dorsal site, and infected with live activated Staphylococcus aureus broth (1x10 8 CFU/ml), and monitored for the period of infection and healing . 
Result and Discussion
Lipid A separation Lipid A was split up by mild acid hydrolysis from the lipopolysaccharide of Proteus mirabilis. Amount of recovered lipid A was obtained from both collected LPS of pathogenic P.mirabilis isolate and standard bacteria (28.5 and 18.5) mg from (150 and 95mg) mg of LPS.
Respectively, approximately represented 20% of LPS amount. The recovered Lipid A in present study disagreed with that reported by Lukasiewicz and coworkers (12) found the recovered amount was 11-16% of LPS. This differentiation may be due to, structural analysis of lipid A within individual organisms resulting from different growth conditions (e.g. temperature), as well as among various organisms yields a remarkable amount of variation (13) .Lipid A diversity has been attributed to the action of "latent" enzyme that modifies the biochemically conserved lipid A molecule (14) , these variations in lipid A structure may contribute to bacterial virulence by mitigating early innate immune defense responses to infection (15(. Heat and mild acid hydrolysis method was considered a sufficient to disrupt the heat labile linkage between lipid A backbone and the ketodeoxyoctanoate (KDO) in the LPS core, as well the insolubility of lipid A in water made it easier to separate by centrifugation (9) .
In vivo test: Lethal Dose 50 (LD50) of lipid A
LD50 of lipid A was identified; it was 0.6 ϻg/ml, this result was confirmed to that obtained by (10).
Quantitative determination of interleukins 1β, 2, 10, TNF alpha, IFN-γ by ELISA
The serum levels of five cytokines (IL-1β, IL-2, IL-10, TNF-α, IFN-γ) were assessed in treated groups and compared with the control groups.
Interleukin 1β
This interleukin is one of IL-1 member, possess a strong pro-inflammatory effect, produced by various cell types including peripheral blood monocytes, macrophages, Bcells, Th lymphocytes and NK cells (16) . The results of IL-1β in this study revealed, a significant decrease (P≤0.05) or no effect in most treated groups except that treated intraperitoneal (i.p) with lipid A of isolated bacteria, these results reflect extracted lipid A was acting perfectly as an adjuvant with the vaccine administered i.p. Since this interleukin is pro-inflammatory material, therefore its good in stimulation both immune responses with low toxicity, which was proved by Okemoto et al., (17) they mentioned, lipid A failed to induce activation of caspase-1, which catalyzes IL-1beta precursor processing. These results suggest that an immune response without activation of caspase-1 led to lowering toxicity of this adjuvant, also IL1beta promotes cell growth, tissue repair, and immune response regulation and have a significant role in many chronic and acute inflammatory diseases (18, 19) . On the other hand, the decline in its concentration for other routes 
Interleukin (IL)-10 and interferon (IFN)-γ
Interleukin-10 was identified as a "cytokine synthesis inhibitory factor" which is a product of Th 2 cells following protein or antigenic stimulation that, block cytokine production from Th 1 cells. IL-10 achieved this effect by inhibiting the ability of macrophages and dendritic cells to activate Th 1 cells (24), however, IL-10 can also be produced by most if not all CD4+ T cell subsets, including Th 1 and Th 17 cells, B cells, neutrophils, and macrophages. The investigations demonstrated that T-regular cells serve as major source of IL-10, and by which regulate the immune response (25) . In this regard, it has been found that IL-10 inhibits the protective immune response to pathogens by blocking the production of pro-inflammatory cytokines, such as TNF-α. It's also capable to inhibit phagocytosis and microbial killing through limiting the production of reactive oxygen and nitrogen intermediates in response to INF-γ (26, 27) . IL-10 enhances B cells survival, proliferation, and differentiation and modulates class-switch recombination and induces the IgG production. Furthermore, the overexpression induces anti-inflammatory cytokines in B cells (28) . The recent result of this study showed the level of IL-10 revealed a significance elevation (P≤0.05) in all treated groups, in addition to the positive comparable adjuvant of control groups. These results reflected the compatibility of lipid A to act as adjuvant like other types of usable one. In addition confirmed that previously mentioned about IL-1 β, table (1) .The results were agreed with that reported by Salkowski and cohorts (29) they suggested that enhanced production of IL-10 by MPL-stimulated macrophages may contribute to reducing the toxicity of MPL through its negative action on induction of cytokines. These findings assist in understanding the cellular mechanisms by which MPL induces host cell activation and subsequent adjuvant properties. Therefore according to the results, lipid A may be safe to use as an adjuvant, as well as lipid A action on IL-10, looks like that of MPL.
Interferon-γ is synthesized mostly by Th 1 lymphocytes, after their activation with immune and inflammatory stimuli, rather than viral infection (30) . Interestingly, natural killer cells can furthermore function as "adaptive effectors" once activated by T cell-induced IFN-γ or when IgG eventually elicits antibody-dependent cell cytotoxicity (31, 32) . IFN-γ secreted to activate macrophages and to induce their microbicidal functions (33) . Although it's is essential for the development of an immune response, that prolongs the lifespan of an infected animal (34) .IFN-γ/IL-10 ratio reflecting the Th 1 /Th 2 balance in serum (35) .
The present results of this cytokine showed a significance increasing (P≤0.05) in the levels of all treated and positive adjuvants control groups in comparison with the negative control, as well these results reflected the compatibility among adjuvants groups and lipid A table (1), and agreed with Werner-Felmayer and coworkers (36) TNF-α is a cytokine associated with acute and chronic inflammation. It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, and eosinophil's (37).
The results of this cytokine showed variation in its levels according to the route of administration. Both intraperitoneal and subcutaneous routes showed a significant elevation (P≤0.05) in TNF-α level of both lipid A extracts (standard and isolated bacteria), while orally rout showed a significance decreases (P≤0.05) in the level of this cytokine table (1), Therefore it can be considered as a suitable adjuvant, when used orally. lipid A provides another important point about the possibility to be used as antitumor if administered I.P and S/C, throughout elevation of TNF-α level in addition to other cytokines. These results were agreed with that reported by Martin et al ., ( 38) Licensed Under Creative Commons Attribution CC BY vivo) when injected i.p or s/c similar to that effects in vitro, because these routes of administrations are concerned systemic routes, made the macrophages and other mononuclear cells that found in blood or in essential organ such as liver , and spleen to exposed directly to lipid A .
Effect of lipid A on antibody level ( IgG)
The effects of Lipid A on the antibody production in mice were proven. No significant alteration of the IgG antibody level was observed in any treated groups in compared with control one. However, both lipid A of( standard and isolated) bacteria have the capacity to increase the antibody titer, after secondary injection with the antigen for intraperitoneal groups (P≤0.05) only, 
Challenge test
Challenging the mice with prepared killed vaccine and lipid A(as adjuvant) for one week followed with a booster dose, they were monitored after scratching the dorsal region of the animal and infected with virulent S.aureus. The results showed the control group was infected with severe inflammation, abscess and subjected to death within five days, the death began at the second day after infection, while the immunized groups with prepared vaccine showed minor symptoms of inflammation and started to heal from the fifth day and the healing completed after a week from the booster dose. These results agreed with that reported by Roquillyet al., (45) 
